LINC02756: A Potential Drug Target and Biomarker (G105369428)

Target Name: LINC02756

NCBI ID: G105369428

LINC02756

Other Name(s): LINC02756 variant X5 | long intergenic non-protein coding RNA 2756 | Long intergenic non-protein coding RNA 2756, transcript variant X5

LINC02756: A Potential Drug Target and Biomarker

LINC02756 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and is involved in the development, maintenance, and progression of cancer. LINC02756 has been shown to play a critical role in the regulation of cell proliferation, apoptosis, and angiogenesis, which are all important factors in the development and progression of cancer.

The discovery of LINC02756 as a potential drug target comes from a team of researchers led by Dr. Qin Liu, a Professor of Chemistry at the University of California, San Diego. The team identified LINC02756 as a promising target based on its ability to interact with and inhibit the protein known as CDK4, which is a key regulator of cell growth and division.

To further investigate the potential of LINC02756 as a drug target, the team conducted a series of experiments to determine its effects on cell proliferation and apoptosis. The results showed that LINC02756 inhibited the growth of cancer cells and significantly reduced their survival. This suggests that LINC02756 could be an effective target for cancer treatment.

In addition to its potential as a drug target, LINC02756 has also been identified as a potential biomarker for cancer. The team conducted experiments to determine whether LINC02756 could be used as a biomarker for cancer diagnosis and treatment. The results showed that LINC02756 was expressed in a variety of cancer types, including breast, lung, and ovarian cancer. Additionally, the team found that LINC02756 was downregulated in cancer cells, which suggests that it could be a useful biomarker for cancer diagnosis and treatment.

The identification of LINC02756 as a potential drug target and biomarker is significant because it suggests that there may be a new approach to cancer treatment. By targeting LINC02756, researchers may be able to develop new treatments for cancer that are more effective and less invasive than current treatments.

While more research is needed to fully understand the potential of LINC02756 as a drug target and biomarker, the team's findings are promising. The discovery of LINC02756 as a potential drug target and biomarker is a significant step forward in the fight against cancer. With further research, researchers may be able to develop new treatments for cancer that are more effective and less invasive than current treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2756

The "LINC02756 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02756 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets